Imipramine Tillomed Laboratories

Imipramine, the active ingredient in Imipramine Tillomed Laboratories, is a tricyclic antidepressant presented as an oral tablet for systemic use. It is prescribed for the management of major depressive disorder, nocturnal enuresis in children, and panic disorder, primarily in adult patients.

GNH USA supplies Imipramine Tillomed Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulatory‑approved products to health‑care institutions across Europe, Asia and the Americas, ensuring quality and traceability with reliable delivery.

Imipramine is a tricyclic antidepressant that modulates monoamine neurotransmission and is used for several psychiatric and urological conditions. - Major depressive disorder: alleviates depressive symptoms by improving mood, energy, and sleep in adult patients. - Enuresis: reduces nighttime urinary leakage in children by influencing bladder control mechanisms. - Panic disorder: decreases frequency and severity of panic attacks through anxiolytic effects.

Imipramine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth: reduced salivation leading to throat discomfort. - Constipation: slowed gastrointestinal motility. - Drowsiness: increased sedation, especially at treatment initiation. - Blurred vision: transient visual disturbances. - Weight gain: modest increase in body weight. - Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythms, particularly in patients with pre‑existing heart disease. - Seizures: lowered seizure threshold, risk higher with overdose. - Severe hypotension: sudden drop in blood pressure causing fainting. - Hepatic toxicity: liver enzyme elevations or hepatitis. - Agranulocytosis: marked reduction in white blood cells. - Suicidal thoughts: emergence or worsening of suicidal ideation.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific safety concerns. - Cardiovascular assessment: review cardiac history and perform ECG in patients with known heart disease. - CNS monitoring: observe for signs of increased anxiety, agitation, or suicidal thoughts. - Drug interactions: assess concomitant medications that may affect cardiac conduction or serotonin levels. - Age considerations: start at lower doses in elderly patients to reduce anticholinergic burden. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imipramine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome and hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents: increased serotonin syndrome risk. - Other tricyclic antidepressants: additive cardiotoxic effects. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise imipramine plasma levels.

Moderate Interactions (Monitor Closely): - Antihistamines and anticholinergics: enhanced anticholinergic side effects. - Alcohol: potentiates CNS depression and dizziness. - CNS depressants (e.g., benzodiazepines): increased sedation. - Diuretics: may exacerbate orthostatic hypotension. - QT‑prolonging drugs: monitor ECG for arrhythmia risk.